Orion Oyj (ORINF) Income Statement Analysis

See more : Hankyu Hanshin REIT, Inc. (8977.T) Income Statement Analysis – Financial Results

Complete financial analysis of Orion Oyj (ORINF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orion Oyj, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Yue Yuen Industrial (Holdings) Limited (0551.HK) Income Statement Analysis – Financial Results
Red Mountain Mining Limited (RMX.AX) Income Statement Analysis – Financial Results
Nippon Shinyaku Co., Ltd. (NPNKF) Income Statement Analysis – Financial Results
Jupiter Wagons Limited (JWL.BO) Income Statement Analysis – Financial Results
Iron Horse Acquisitions Corp. Warrant (IROHW) Income Statement Analysis – Financial Results

Orion Oyj (ORINF)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.orion.fi

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	1.19B	1.34B	1.04B	1.08B	1.05B	977.40M	1.08B	1.07B	1.02B	1.02B	1.01B	980.30M	917.90M	849.90M	771.50M	710.70M	683.60M	311.20M	1.90B	1.95B
Cost of Revenue	531.90M	491.70M	447.50M	427.00M	417.60M	387.90M	440.60M	421.70M	405.80M	401.70M	393.50M	350.00M	305.10M	283.20M	265.20M	230.00M	204.20M	105.20M	1.36B	1.43B
Gross Profit	657.70M	849.00M	593.50M	651.10M	633.30M	589.50M	644.10M	651.80M	609.80M	613.60M	613.40M	630.30M	612.80M	566.70M	506.30M	480.70M	479.40M	206.00M	542.30M	516.10M
Gross Profit Ratio	55.29%	63.33%	57.01%	60.39%	60.26%	60.31%	59.38%	60.72%	60.04%	60.44%	60.92%	64.30%	66.76%	66.68%	65.63%	67.64%	70.13%	66.20%	28.52%	26.52%
Research & Development	126.90M	135.80M	117.70M	123.20M	119.30M	104.00M	105.10M	118.20M	108.10M	106.20M	101.90M	104.80M	87.50M	85.50M	95.20M	103.40M	90.00M	43.10M	72.40M	71.00M
General & Administrative	74.80M	68.80M	47.90M	48.90M	47.80M	43.00M	49.10M	48.70M	46.20M	43.30M	44.50M	45.30M	40.60M	39.30M	50.20M	51.50M	-107.00M	20.40M	-155.30M	-167.30M
Selling & Marketing	224.80M	210.30M	191.00M	204.30M	215.70M	195.30M	198.60M	194.70M	190.40M	193.40M	204.90M	205.70M	204.80M	188.90M	160.00M	143.90M	139.80M	63.20M	203.30M	215.10M
SG&A	299.60M	279.10M	238.90M	253.20M	263.50M	238.30M	247.70M	243.40M	236.60M	236.70M	249.40M	251.00M	245.40M	228.20M	210.20M	195.40M	32.80M	83.60M	48.00M	47.80M
Other Expenses	-43.70M	-2.30M	-800.00K	-1.80M	-1.10M	1.80M	400.00K	400.00K	400.00K	400.00K	300.00K	500.00K	-3.00M	-1.20M	-6.00M	-11.60M	2.00M	-11.60M	246.60M	-600.00K
Operating Expenses	382.80M	412.60M	355.80M	374.60M	381.70M	338.60M	351.20M	359.70M	342.10M	342.00M	348.90M	350.10M	329.90M	312.50M	299.40M	287.20M	292.60M	115.10M	367.00M	385.00M
Cost & Expenses	914.70M	904.30M	803.30M	801.60M	799.30M	726.50M	791.80M	781.40M	747.90M	743.70M	742.40M	700.10M	635.00M	595.70M	564.60M	517.20M	496.80M	220.30M	1.73B	1.82B
Interest Income	2.40M	1.00M	100.00K	200.00K	400.00K	300.00K	200.00K	100.00K	200.00K	500.00K	400.00K	800.00K	5.00M	4.20M	5.10M	7.60M	2.90M	3.50M	2.40M	2.30M
Interest Expense	5.20M	1.50M	1.00M	900.00K	2.30M	4.50M	4.50M	4.60M	5.20M	5.50M	4.00M	2.60M	6.00M	5.90M	8.40M	8.50M	1.10M	3.00M	3.90M	3.90M
Depreciation & Amortization	51.50M	47.50M	45.10M	55.30M	56.10M	40.80M	38.60M	40.30M	41.80M	39.60M	38.50M	40.00M	42.50M	38.90M	34.40M	31.60M	31.60M	17.20M	47.70M	57.00M
EBITDA	328.60M	489.60M	288.70M	334.80M	309.60M	293.90M	322.50M	355.60M	309.30M	312.90M	306.50M	319.20M	320.20M	293.70M	242.80M	219.90M	226.10M	108.10M	231.60M	191.00M
EBITDA Ratio	27.62%	36.47%	27.39%	31.11%	29.40%	30.07%	30.65%	31.08%	30.43%	30.76%	30.35%	32.79%	36.01%	34.99%	31.95%	31.67%	32.46%	34.74%	11.87%	9.76%
Operating Income	274.90M	439.60M	243.30M	280.10M	252.80M	252.80M	293.00M	314.60M	266.60M	272.40M	267.70M	280.90M	282.90M	254.20M	206.90M	193.50M	186.80M	90.90M	175.30M	131.10M
Operating Income Ratio	23.11%	32.79%	23.37%	25.98%	24.06%	25.86%	27.01%	29.31%	26.25%	26.83%	26.59%	28.65%	30.82%	29.91%	26.82%	27.23%	27.33%	29.21%	9.22%	6.74%
Total Other Income/Expenses	-3.00M	700.00K	-1.00M	-1.80M	-2.00M	-4.40M	-6.40M	-3.70M	-4.30M	-4.60M	-3.70M	-5.40M	-900.00K	-1.60M	-3.20M	-9.40M	8.60M	500.00K	4.70M	-900.00K
Income Before Tax	271.90M	440.30M	242.30M	278.30M	250.80M	248.40M	286.50M	310.90M	262.30M	267.80M	264.00M	279.30M	282.00M	252.60M	203.70M	184.20M	195.40M	91.40M	180.00M	130.20M
Income Before Tax Ratio	22.86%	32.84%	23.28%	25.81%	23.87%	25.41%	26.41%	28.96%	25.83%	26.38%	26.22%	28.49%	30.72%	29.72%	26.40%	25.92%	28.58%	29.37%	9.46%	6.69%
Income Tax Expense	55.10M	90.80M	48.50M	58.40M	50.50M	51.00M	60.50M	61.90M	54.20M	56.60M	57.80M	70.40M	72.40M	67.90M	52.30M	47.80M	50.00M	24.80M	47.90M	38.10M
Net Income	216.80M	349.50M	193.80M	219.90M	200.40M	330.30M	226.00M	249.00M	208.20M	211.30M	206.20M	208.90M	209.50M	184.70M	151.40M	136.30M	145.40M	66.60M	131.10M	90.50M
Net Income Ratio	18.22%	26.07%	18.62%	20.40%	19.07%	33.79%	20.84%	23.20%	20.50%	20.81%	20.48%	21.31%	22.82%	21.73%	19.62%	19.18%	21.27%	21.40%	6.89%	4.65%
EPS	1.54	2.49	1.38	1.57	1.43	2.35	1.61	1.77	1.48	1.50	1.46	1.47	1.49	1.31	1.07	0.97	1.02	0.47	0.93	0.64
EPS Diluted	1.54	2.49	1.38	1.57	1.43	2.35	1.61	1.77	1.48	1.50	1.46	1.47	1.49	1.31	1.07	0.97	1.02	0.47	0.93	0.64
Weighted Avg Shares Out	140.78M	140.50M	140.55M	140.51M	140.57M	140.68M	140.56M	140.67M	140.81M	140.67M	141.01M	140.91M	140.83M	140.92M	140.97M	141.00M	141.26M	141.26M	141.26M	141.26M
Weighted Avg Shares Out (Dil)	140.36M	140.59M	140.55M	140.51M	140.57M	140.68M	140.57M	140.67M	140.81M	140.67M	141.01M	140.91M	140.83M	140.92M	140.97M	141.00M	141.26M	141.26M	141.26M	141.26M

ORION Holdings Corp. (ORINF) Q3 2024 Earnings Call Transcript

October 29, 2024seekingalpha.com

ORION Holdings Corp. (OTCPK:ORINF) Q3 2024 Results Conference Call October 29, 2024 7:30 AM ET Company Participants Tuukka Hirvonen - Head of IR Rene Lindell - CFO Outi Vaarala - SVP, Innovative Medicines and Research & Development Conference Call Participants...

Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why

September 26, 2024zacks.com

Orion OYJ (ORINY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength"...

Is Orion OYJ (ORINY) a Solid Growth Stock? 3 Reasons to Think "Yes"

August 16, 2024zacks.com

Orion OYJ (ORINY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ORION Holdings Corp. (ORINF) Q2 2024 Earnings Call Transcript

August 9, 2024seekingalpha.com

ORION Holdings Corp. (OTCPK:ORINF) Q2 2024 Results Conference Call August 8, 2024 6:30 AM ET Company Participants Tuukka Hirvonen - Investor Relations & Financial Communications Officer Liisa Hurme - President, CEO & Chairman of Executive Management Board Rene Lindell -...

ORION Holdings Corp. (ORINF) Q1 2024 Earnings Call Transcript

April 27, 2024seekingalpha.com

ORION Holdings Corp. (OTCPK:ORINF) Q1 2024 Earnings Conference Call April 25, 2024 6:30 AM ET Company Participants Tuukka Hirvonen - Investor Relations & Financial Communications Officer Liisa Hurme - President, CEO & Chairman of Executive Management Board Jari Karlson -...